PRINT OUT

Product Pipeline

Aug 09. 2017

<Domestic>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
Phase III GA101
(obinutuzumab)
hematologic
malignancies
indolent non-Hodgkin's
lymphoma
Licensed‐in
from Chugai
Pharmaceutical
Co., Ltd.
Co‐developed with
Chugai Pharmaceutical Co., Ltd.
Phase III NS-304
(selexipag)
intractable disease・
orphan disease
chronic thromboembolic
pulmonary hypertension
Nippon shinyaku Co‐developed
with Actelion
Pharmaceuticals Japan Ltd.
Phase II NS-304
(selexipag)
cardiovascular arteriosclerosis obliterans Nippon shinyaku Nippon shinyaku
Phase II NS-580 gynecology endometriosis Nippon shinyaku Nippon shinyaku
Phase I/II NS-065/
NCNP-01
intractable disease・
orphan disease
duchenne muscular dystrophy Nippon shinyaku/
National Center
of Neurology
and Psychiatry
Nippon shinyaku
Phase I NS-32 gynecology iron deficiencyanemia Licensed‐in from
Pharmacosmos A/S
Nippon shinyaku
Preparation
for
development
NS-917 hematologic
malignancies
relapsed/refractory
acute myeloid leukemia
Licensed‐in from
Delta-Fly Pharma, Inc.
Nippon shinyaku
Preparation
for
development
NS-73 hematologic
malignancies
veno-occlusive disease Licensed‐in
from Jazz
Pharmaceuticals plc
Nippon shinyaku
Preparation
for
development
NS-87 hematologic
malignancies
secondary acute
myeloid leukemia
Licensed‐in
from Jazz
Pharmaceuticals plc
Nippon shinyaku

<Overseas>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
Preparation
for NDA
NM441
(prulifloxacin)
anti-infection bacterial infections Nippon shinyaku Licensed‐out to
Lee's Pharmaceutical
Holdings Limited
Phase II NS-065/
NCNP-01
intractable disease・
orphan disease
duchenne muscular dystrophy Nippon shinyaku/
National Center
of Neurology
and Psychiatry
Nippon shinyaku
Phase I/II NS-018 hematologic
malignancies
myelofibrosis Nippon shinyaku Nippon shinyaku
page-top